Key Points
- Gregg Williams, a Vivani Medical director, bought 1,575,231 shares on March 15 at an average price of $1.07 for $1,685,497.17, increasing his holdings to 31,357,183 shares (a 5.29% boost).
- This purchase follows two large insider buys on Jan 15 (1,737,765 shares at $1.14, ~$1.98M) and Jan 27 (1,351,351 shares at $1.48, ~$2.00M), meaning Williams has spent over $5.66 million on VANI stock recently.
- Vivani shares rose about 10.9% on the news; the company has a market cap near $95.4M and a MarketBeat consensus rating of Hold with a $4.00 price target.
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams acquired 1,575,231 shares of the company's stock in a transaction dated Sunday, March 15th. The shares were bought at an average cost of $1.07 per share, with a total value of $1,685,497.17. Following the purchase, the director owned 31,357,183 shares of the company's stock, valued at approximately $33,552,185.81. This trade represents a 5.29% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Gregg Williams also recently made the following trade(s):
- On Tuesday, January 27th, Gregg Williams bought 1,351,351 shares of Vivani Medical stock. The stock was purchased at an average price of $1.48 per share, for a total transaction of $1,999,999.48.
- On Thursday, January 15th, Gregg Williams bought 1,737,765 shares of Vivani Medical stock. The stock was purchased at an average cost of $1.14 per share, for a total transaction of $1,981,052.10.
Vivani Medical Stock Up 10.9%
NASDAQ:VANI opened at $1.22 on Tuesday. The company has a fifty day moving average of $1.28 and a 200 day moving average of $1.36. Vivani Medical, Inc. has a 52 week low of $0.91 and a 52 week high of $1.92. The firm has a market capitalization of $95.37 million, a P/E ratio of -2.71 and a beta of 3.17.
Analysts Set New Price Targets
Several brokerages have recently commented on VANI. Wall Street Zen raised shares of Vivani Medical to a "sell" rating in a research note on Saturday, November 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Vivani Medical in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Vivani Medical presently has a consensus rating of "Hold" and a consensus price target of $4.00.
Check Out Our Latest Research Report on VANI
Institutional Trading of Vivani Medical
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VANI. State Street Corp boosted its holdings in Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company's stock valued at $178,000 after acquiring an additional 16,070 shares in the last quarter. Susquehanna International Group LLP raised its holdings in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock worth $46,000 after purchasing an additional 16,200 shares in the last quarter. Citadel Advisors LLC bought a new position in Vivani Medical in the 3rd quarter worth $26,000. Panagora Asset Management Inc. purchased a new stake in shares of Vivani Medical in the 2nd quarter worth about $25,000. Finally, Jane Street Group LLC purchased a new stake in shares of Vivani Medical in the 4th quarter worth about $60,000. Hedge funds and other institutional investors own 6.78% of the company's stock.
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.
The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
